Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shuttle Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $2.89 Mil.
Shuttle Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shuttle Pharmaceuticals Holdings EV-to-EBIT Related Terms
Shuttle Pharmaceuticals Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shuttle Pharmaceuticals Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shuttle Pharmaceuticals Holdings's EV-to-EBIT falls into.
Shuttle Pharmaceuticals Holdings's current Enterprise Value is $0.84 Mil.
Shuttle Pharmaceuticals Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shuttle Pharmaceuticals Holdings (SHPH) has a EV-to-EBIT of -0.08 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Shuttle Pharmaceuticals Holdings' EV-to-EBIT too high?
Shuttle Pharmaceuticals Holdings' current EV-to-EBIT is -0.08. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' EV-to-EBIT compare to PLSH and SKYI?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 690 companies for EV-to-EBIT. This places Shuttle Pharmaceuticals Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current EV-to-EBIT is -0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current EV-to-EBIT of -0.08. The current EV-to-EBIT is -0.08. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current EV-to-EBIT is -0.08 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shuttle Pharmaceuticals Holdings Business Description
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score
Get the complete analysis for SHPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPH has been successfully added to your 
